[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nonalcoholic-fatty-liver-disease-nafld\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nonalcoholic-fatty-liver-disease-nafld":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,37,80,120],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100644362","clinical-course-and-biomarkers-associated-with-nonalcoholic-fatty-liver-disease-nafld-in-chinese-patients-with-obesity-100644362",false,"NCT07662356","Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity","Inclusion Criteria:\n\n* Age 18 years or above\n* Chinese ethnicity\n* Patient undergoing obesity surgery at The Prince of Wales Hospital\n\nExclusion Criteria:\n\n* Endocrine causes of obesity\n* Active uncontrolled psychiatric illness\n* Active substance abuse\n* Alcohol intake exceeding 30 grams per day in males or 20 grams per day in females\n* Presence of other co-existing liver disease, as evidenced by known history of positive viral hepatitis serology\n* History of decompensated liver disease\n* Unlikely to comply with management protocol\n* Failure to give consent","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","OBSERVATIONAL","Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in many parts of the world. NAFLD can progress to nonalcoholic steatohepatitis (NASH) and result in cirrhosis and liver cancer. Despite NAFLD is common, there are a lot of knowledge gaps about this common disease including the progression from NAFLD to NASH and from fibrosis to cirrhosis, efficacious treatment strategies, etc.\n\nIn this study, we aim to investigate the clinical course and biomarkers associated with NAFLD in a group of obese patients with or without known history of NAFLD at baseline undergoing laparoscopic bariatric surgery. During laparoscopic surgery, subjects consented to participate will have liver biopsies performed under direct vision and sent for histological analysis and scoring. The patients will undergo comprehensive clinical and biochemical assessment before and after the surgical procedures.\n\nThe prevalence of NAFLD and clinical course of this group of patients with obesity will be assessed using histology as the gold standard. Clinical characteristics and biomarkers associated with NAFLD will be identified.",[23],"Nonalcoholic Fatty Liver Disease (NAFLD)","RECRUITING","2026-06-17",{"date":27,"type":28},"2026-06-23","ACTUAL",{"date":30,"type":28},"2019-12-16",{"date":32,"type":19},"2030-12-31",{"name":34,"class":35},"Chinese University of Hong Kong","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":45,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":62,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100600119","the-impact-of-pectin-supplementation-on-systematic-inflammation-pathway-gut-microbiome-and-metabolic-health-in-patients-with-metabolic-dysfunction-associated-steatotic-liver-disease-masld-100600119","NCT07093346","The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Randomised, Placebo-Controlled, Dietary Intervention Study","PEC-MASLD","Inclusion Criteria:\n\nInclusion criteria for the main study:\n\n* Patients with clinical diagnosis of MASLD (formerly termed non-alcoholic fatty liver disease (NAFLD)), having assessment suggesting that liver fat \\> 5% (e.g. histological evidence or\u002F and Transient Elastography using Controlled Attenuation Parameter (CAP)- FibroScan™ in the past month and\u002For liver imaging (such as ultrasound, computerized tomography (CT) or magnetic resonance imaging (MRI)).\n* Participants willing and able to give informed consent for participation in the study.\n* Participants aged ≥18 years who have a body mass index (BMI) between 18.5 and 39.9 kg\u002Fm2 and stable weight (weight gain or loss ≤ 3kg) for the past 3 months.\n* For diabetic participants: controlled blood glucose levels Haemoglobin A1C (HbA1c) \\\u003C7.0% (\\\u003C53 mmol\u002Fmol) \\[1\\].\n* Able to undergo CAP-FibroScan™.\n\nInclusion criteria for healthy participants who will have MRI scans:\n\n* Participants willing and able to give informed consent for participation in the study.\n* Participants aged ≥18 years.\n* participants with CAP\\\u003C250 kpa\\\u003C8kP by a FibroScan™ within the past 6 months.\n\nExclusion Criteria:\n\nExclusion criteria for the main study:\n\n* Have allergy toward soya, milk or chocolate.\n* Have allergy toward pectin.\n* Participants on vegan diet.\n* Have eating disorders or difficulties or gastrointestinal conditions e.g. malabsorptive conditions such as coeliac, Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD) or gastroparesis.\n* Have chronic malnutrition condition.\n* History of major surgery which potentially limits participation or completion of the study.\n* History of previous intestinal surgery known to affect food intake or digestive function, including bariatric surgery.\n* Use of antibiotics, antifungal medications, probiotics or prebiotics 90 days before the start of the study.\n* Are taking the following medications: immunosuppressants, amiodarone and\u002For perhexiline.\n* Are currently following or anticipated to commence a specialised commercially available weight loss diet and\u002For program or concomitant use of any weight loss medication or herbal weight loss products.\n* History of side effects towards probiotics or prebiotics.\n* History or current psychiatric illness.\n* History or current neurological condition (e.g. epilepsy).\n* Participants with other liver abnormalities.\n* Evidence of monogenic metabolism diseases such as Lysosomal acid lipase deficiency (LALD), Wilson disease, Hypobetalipoproteinemia, or inborn errors of metabolism.\n* Have had a weight change exceeding 3 kg within 3 months.\n* Uncontrolled diabetes, active malignancy, or chronic infections.\n* Having symptoms of active infection.\n* Excessive alcohol intake defined as self-reported intakes greater than 21 units per week in men, and 14 units per week in women.\n* Participants who are pregnant, breast feeding or actively planning pregnancy will be excluded from the study.\n* Participation in any other trial in the last 3 months.\n\nExclusion criteria for healthy volunteers MRI scans and patients optional MRI scans:\n\n* Contraindications for MRI scanning: having pacemakers, defibrillators, neurostimulators, prohibited medical implants, and foreign bodies (e.g. bullets, shrapnel, metal slivers), history of metallic foreign body in eye(s) and penetrating eye injury that could present a risk during an MRI scan.\n* Difficulty breathing or inability to lie flat, as well as conditions that could worsen under stress (such as anxiety or panic disorders, claustrophobia, uncontrolled hypertension, or seizure disorders) severe enough to prevent undergoing an MRI.",true,{"count":47,"type":19},45,"INTERVENTIONAL",[50],"NA","The goal of this clinical trial is to learn if daily supplementation with Low-methoxy (LM) pectin (polysaccharides extracted from citrus peels), which are commonly found in the UK diet (not pharmacological agents), can reduce systemic inflammation and improve gut microbiota composition in adults recently diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The main question it aims to answer is:\n\n-How does dietary Low-methoxy (LM) pectin supplementation affect systematic inflammation pathways such as those mediated by gut microbiota composition and what are the impacts on general metabolic indicators in individuals with MASLD?\n\nResearchers will compare a group taking 15g of LM-pectin with 10g of cocoa powder to a placebo group receiving 10g of placebo with 10g of cocoa powder to see if LM-pectin has measurable effects on inflammation and gut microbiota.\n\nParticipants will:\n\n* Take a daily supplement for 6 weeks: either 15g of LM-pectin with 10g of cocoa powder (intervention), or 10g of placebo with 10g of cocoa powder (control)\n* Provide stool and fasting blood samples before and after the intervention\n* Undergo anthropometric measurements (weight, height, waist\u002Fhip ratio, and blood pressure)\n* Complete a case report form (CRF) including demographics and health\u002Fmedical history\n* Undergo a FibroScan™ to assess liver health\n* (Optional) Participate in MRI scans to evaluate gut permeability",[53,23,54,55,56,57,58,59,60,61],"Nonalcoholic Fatty Liver Disease","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","MASLD","NAFLD","Metabolic Dysfunction-Associated Steatotic Liver Disease","NAFLD (Nonalcoholic Fatty Liver Disease)","NAFLD (Non-alcoholic Fatty Liver Disease)","NAFLD - Non-Alcoholic Fatty Liver Disease","NAFLD - Nonalcoholic Fatty Liver Disease",[63,64,55,56,53,65,66,67,68,69,57],"LM pectin","pectin","Systemic Inflammatory Response","Dietary Fiber","Dietary Fibre","Diet","gut microbiota","2025-07-22",{"date":72,"type":28},"2025-07-30",{"date":74,"type":28},"2025-06-10",{"date":76,"type":19},"2027-03-31",{"name":78,"class":35},"University of Nottingham",3,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":48,"phases":91,"briefSummary":92,"conditions":93,"keywords":101,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":36},"100598184","gepaktiv-vs-udca-and-ademetionine-in-mafld-with-hepatomegaly-100598184","NCT07068191","Gepaktiv vs UDCA and Ademetionine in MAFLD With Hepatomegaly","Randomized Comparative Clinical Study of the Dietary Supplement \"Gepaktiv\" (International Name: Phenomenon) in Comparison With Ursodeoxycholic Acid (UDCA) and Ademetionine in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) and Hepatomegaly","HEPACT","Inclusion Criteria:\n\n* Age 18 to 65 years\n* Confirmed diagnosis of metabolic-associated fatty liver disease (MAFLD)\n* Hepatomegaly confirmed by ultrasound (≥3 cm craniocaudal liver enlargement)\n* ALT level between 90-150 U\u002FL\n* Steatosis ≥260 dB\u002Fm by FibroScan (CAP)\n* Fibrosis ≥11 kPa by transient elastography (FibroScan)\n* Ability to comply with study procedures\n* Signed informed consent\n\nExclusion Criteria:\n\n* Liver cirrhosis or hepatocellular carcinoma\n* Pregnancy or lactation\n* Known allergy to any of the study medications or supplement components\n* Gallstones or biliary obstruction\n* Shrunken liver on imaging\n* Hepatic cysts (simple liver cysts\u002Fbiliary cysts)\n* Liver nodules (focal liver lesions)","65 Years",{"count":90,"type":19},90,[50],"This study compares the effectiveness of the dietary supplement Gepaktiv with standard medications (UDCA and Ademetionine) in patients with fatty liver disease (MAFLD) and liver enlargement (hepatomegaly).\n\nKey points:\n\n* Participants will receive either Gepaktiv, UDCA, or Ademetionine for 15 days\n* Doctors will monitor liver health through blood tests and ultrasound scans\n* The study will check if Gepaktiv helps improve liver function as effectively as standard treatments.\n\nMain measurements:\n\n* Changes in liver enzyme levels (ALT, AST)\n* Reduction in liver size\n* Improvement in fat accumulation (steatosis) measured by FibroScan This research may provide evidence for a new natural option to support liver health.Data analysis will be done by an independent biostatistics",[94,95,96,23,97,98,99,100],"Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)","Hepatomegaly","Nonalcoholic Fatty Liver (NAFL)","Fatty Liver","Fatty Liver, Alcoholic","Fatty Liver, Nonalcoholic","Fatty Liver Disease",[95,102,103,104,105,106,107,108,109,110,97],"Gepaktiv","Metabolic dysfunction-associated fatty liver disease (MAFLD)","metabolic dysfunction-associated steatotic liver disease (MASLD)","Nonalcoholic fatty liver disease (NAFLD)","liver diseases","Nonalcoholic fatty liver (NAFL)","Liver","Liver steatosis","Dietary supplements","2025-07-19",{"date":113,"type":28},"2025-07-23",{"date":115,"type":28},"2025-06-19",{"date":117,"type":19},"2025-08",{"name":119,"class":35},"Phenomen Pharma",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":124,"acronym":125,"eligibilityCriteria":126,"healthyVolunteers":45,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":127,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":129,"conditions":130,"keywords":132,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":36},"100329687","quantitative-ultrasound-techniques-for-diagnosis-of-nonalcoholic-steatohepatitis-100329687","NCT03572465","Quantitative Ultrasound Techniques for Diagnosis of Nonalcoholic Steatohepatitis","QUS in NASH","Inclusion Criteria:\n\n* Are at least 18 years old at screening;\n* Able to comprehend and willingness to provide voluntary consent;\n* Understand French or English;\n* NAFLD\u002FNASH subjects:\n\n  * Have a suspected or known NAFLD or NASH;\n  * Must undergo a liver biopsy as part of their clinical standard of care\n* Non-NAFLD volunteers:\n\n  * Do not have a suspected or known NAFLD or NASH\n\nExclusion Criteria:\n\n* Are pregnant or trying to become pregnant;\n* Have a weight or girth preventing them from entering the MR magnet bore;\n* Are unable to understand or unwilling to provide written informed consent for this study;\n* Non-NAFLD volunteers:\n\n  * Have risk factors for developing liver steatosis (type 2 diabetes mellitus, alcohol consumption \\>60g of alcohol per day, lipogenic medication and body mass index \\>25 kg\u002Fm2);\n  * Have a liver steatosis (defined as MRI-proton density fat fraction \\\u003C5%);\n* NAFLD\u002FNASH subjects:\n\n  * Have other causes of chronic liver disease;\n  * Have a liver transplant",{"count":128,"type":19},102,"Nonalcoholic fatty liver disease is the most common liver disease in Western countries, due in large part to its association with type 2 diabetes and obesity. The more advanced form of this disease is known as nonalcoholic steatohepatitis (NASH). If left untreated, NASH can evolve to cirrhosis, the late stage of fibrosis. Once cirrhosis is established, patients are at increased risk of developing gastrointestinal bleeding, liver cancer and liver failure that may require transplantation. A liver biopsy is currently needed to diagnose the severity of fatty liver disease but this is usually not indicated in asymptomatic patients. This procedure requires the insertion of a needle inside the liver to remove a small piece of tissue for examination under microscope. Liver biopsy is an invasive procedure with a small risk of major complications such as bleeding in 0.5% of cases. It is also affected by sub-optimal sampling leading to diagnostic errors\n\nUltrasound is optimum for screening patients with or without symptoms because it is a safe and widely available technology to scan the whole liver. Members of our team have developed Advanced ultrasound techniques that provide unique information not possible with state-of-the-art techniques. Unlike liver biopsy, these techniques would be applicable even in asymptomatic patients because it is non-invasive. This research proposal proposes a novel approach for diagnosis of NASH and will be the first study to measure individual components of NASH (fat, inflammation and fibrosis) with quantitative ultrasound (QUS) scores. This study is timely because NASH is the second leading cause of liver transplantation in North America and is predicted to become the leading indication in the near future.",[23,131],"Nonalcoholic Steatohepatitis (NASH)",[133,134,135,136,137,138,139],"Chronic liver disease","Fibrosis","Elastography","Ultrasound","Magnetic resonance elastography","Diagnostic performance","Sensitivity and specificity","2025-03-14",{"date":142,"type":28},"2025-03-18",{"date":144,"type":28},"2019-10-23",{"date":146,"type":19},"2026-02-28",{"name":148,"class":35},"Centre hospitalier de l'Université de Montréal (CHUM)"]